In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...
Hybrid closed-loop technology effectively helped women stay in target glucose range for longer compared to standard of care
CHICAGO, June 20, 2025 /PRNewswire/ -- A...
HealthRX enhances online platform to offer doctor-prescribed GLP-1 medications like Ozempic® and Zepbound® for adults seeking virtual weight loss support, prescription access, and 24/7 telehealth care
HealthRX enhances online platform to offer doctor-prescribed GLP-1 medications like Ozempic® and Zepbound® for adults seeking virtual weight loss support, prescription access, and 24/7 telehealth care
HONG KONG, June 19, 2025 /PRNewswire/ -- Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased...
According to DelveInsight's analysis, the current developmental pipeline for osteoarthritis is robust, with several companies initiating clinical trials to investigate new treatment options or...
The chronic hepatitis B market size is predicted to surge owing to the increasing prevalence of the disease globally and rising awareness about early...
ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacksOnce-monthly dosing reduced HAE attacks by a...
The overall chronic lower back pain market is expected to boost with the expected launch of emerging therapies such as SP-102 (Scilex Holding), Rexlemestrocel-L...
HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.
Frontiers in Veterinary Science paper reports rapid, significant pain relief with weekly p62-plasmid injections and no significant side-effects
BOSTON, June 13, 2025 /PRNewswire/ -- CureLab...